NG 348

Drug Profile

NG 348

Alternative Names: Membrane bound ligand T-SIGn virus; NG-348

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Bristol-Myers Squibb; PsiOxus Therapeutics
  • Class Oncolytic viruses
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Mar 2018 Phase-I clinical trials in Solid tumours in United Kingdom (IV) (PsiOxus pipeline, March 2018)
  • 12 Dec 2017 PsiOxus Therapeutics receives the Clinical Trial Application approval for NG 348 for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top